Trial · NCT01137474
Adverse events76
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 76
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Mastoiditis | Infections and infestations | Placebo | 0 | 311 | |
| serious | Mastoiditis | Infections and infestations | Dapagliflozin, 2.5 mg (Randomized Before Protocol Amendment 8) | 0 | 166 | |
| serious | Mastoiditis | Infections and infestations | Dapagliflozin, 5 mg (Randomized Before Protocol Amendment 8) | 0 | 165 | |
| serious | Mastoiditis | Infections and infestations | Dapagliflozin 10 mg | 1 | 302 | |
| serious | Craniocerebral injury | Injury, poisoning and procedural complications | Placebo | 0 | 311 | |
| serious | Craniocerebral injury | Injury, poisoning and procedural complications | Dapagliflozin, 2.5 mg (Randomized Before Protocol Amendment 8) | 0 | 166 | |
| serious | Craniocerebral injury | Injury, poisoning and procedural complications | Dapagliflozin, 5 mg (Randomized Before Protocol Amendment 8) | 1 | 165 | |
| serious | Craniocerebral injury | Injury, poisoning and procedural complications | Dapagliflozin 10 mg | 0 | 302 | |
| serious | Fall | Injury, poisoning and procedural complications | Placebo | 0 | 311 | |
| serious | Fall | Injury, poisoning and procedural complications | Dapagliflozin, 2.5 mg (Randomized Before Protocol Amendment 8) | 0 | 166 | |
| serious | Fall | Injury, poisoning and procedural complications | Dapagliflozin, 5 mg (Randomized Before Protocol Amendment 8) | 1 | 165 | |
| serious | Fall | Injury, poisoning and procedural complications | Dapagliflozin 10 mg | 0 | 302 | |
| serious | Cholecystitis acute | Hepatobiliary disorders | Placebo | 0 | 311 | |
| serious | Cholecystitis acute | Hepatobiliary disorders | Dapagliflozin, 2.5 mg (Randomized Before Protocol Amendment 8) | 0 | 166 | |
| serious | Cholecystitis acute | Hepatobiliary disorders | Dapagliflozin, 5 mg (Randomized Before Protocol Amendment 8) | 1 | 165 | |
| serious | Cholecystitis acute | Hepatobiliary disorders | Dapagliflozin 10 mg | 0 | 302 | |
| serious | Intervertebral disc disorder | Musculoskeletal and connective tissue disorders | Placebo | 0 | 311 | |
| serious | Intervertebral disc disorder | Musculoskeletal and connective tissue disorders | Dapagliflozin, 2.5 mg (Randomized Before Protocol Amendment 8) | 1 | 166 | |
| serious | Intervertebral disc disorder | Musculoskeletal and connective tissue disorders | Dapagliflozin, 5 mg (Randomized Before Protocol Amendment 8) | 0 | 165 | |
| serious | Intervertebral disc disorder | Musculoskeletal and connective tissue disorders | Dapagliflozin 10 mg | 0 | 302 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01137474/events